| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd98ad4ee076841fec541542f952f58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 |
| filingDate |
2019-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_751880597df85b44deb112ade276cc8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14b35babe1e0a4a0081059538d50d733
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ba077c93669eab714e792f5628f5fc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81568a5f9b75f53ce22c8cd371f96538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb9c2e74181119869874c3bf710db0a4 |
| publicationDate |
2021-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10940193-B2 |
| titleOfInvention |
Controlled release vaccines and methods for treating Brucella diseases and disorders |
| abstract |
Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus . In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021386848-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023010074-A1 |
| priorityDate |
2010-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |